Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases

M-Type Phospholipase A ₂ Receptor as Target Antigen in Idiopathic Membranous Nephropathy

Laurence H. Beck, Ramon Bonegio, Gérard Lambeau et al. · New England Journal of Medicine · 2009 · 2.3K citations · Full text

Medicine, Immunology, Pathology +17

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede, Kirsten Fischer, Raymonde Busch et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text

Pharmacy, Hematology, Pharmacotherapy +16

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 957 citations · Full text

Life Sciences, Immunology, Oncology +17

Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy

Nicola M. Tomas, Laurence H. Beck, Catherine Meyer‐Schwesinger et al. · New England Journal of Medicine · 2014 · 937 citations · Full text

Life Sciences, Immunology, Pathology +12

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Robert Marcus, Andrew Davies, Kiyoshi Ando et al. · New England Journal of Medicine · 2017 · 788 citations · Full text

Medicine, Immunology, Oncology +14